Do Wall Street Analysts Like Humana Stock?

Humana Inc., a Louisville, Kentucky-based provider of medical and specialty insurance products, has seen its stock soar compared to broader market indexes over the past year. With a market capitalization of $46.7 billion, Humana's shares have risen 36.5%, outpacing the S&P 500 Index's 20.6% gain during the same period. Looking ahead to 2026, HUM stock is projected to increase by 50.3%, surpassing the SPX's 13.9% YTD rise.

JPMorgan recently upgraded Salesforce stock, but Wall Street's sentiment towards Humana remains mixed. Among 26 analysts covering Humana, the consensus rating stands at a Moderate Buy, reflecting a combination of 12 Strong Buy ratings, 13 Holds, and one Strong Sell. Despite this moderate outlook, JPMorgan's analyst Lisa Gill maintained a Neutral rating on Humana and raised the price target to $393, indicating a potential upside of 2.1%. The mean price target of $419.61 suggests a 9% premium to Humana's current stock price.